Maintaining Hold on Allakos: Weighing AK006 Promise Against Clinical Setbacks
Allakos's Promising Drug and Financial Health Garner a Buy Rating
TD Cowen Sticks to Its Hold Rating for Allakos (ALLK)
Allakos Analyst Ratings
Allakos Analyst Ratings
Allakos Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)
Barclays Sticks to Its Sell Rating for Allakos (ALLK)
Allakos Buy Rating: Clinical Promise and Financial Stability Drive Positive Outlook
Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
TD Cowen Remains a Hold on Allakos (ALLK)
Analysts' Top Healthcare Picks: KalVista Pharmaceuticals (KALV), Allakos (ALLK)
Allakos Analyst Ratings
Allakos Extends Losses as Analysts Downgrade on Phase 2 Setback
JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating
Allakos Analyst Ratings
No Data